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Serum concentrations of proangiogenic cytokines (VEGF, bFGF) 
depending on the histopathological types of Hodgkin lymphoma in 
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Background. The different histological types of classical Hodgkin Lym-
phoma (cHL) differ from other percentage share of the Reed-Sternberg 
cells (R-SC) in the affected lymphoid tissue In the Lymphocyte Depletion 
cHL (LDcHL) type are present almost only R-SC. In turn, in the Nodular 
Lymphocyte Predominant Hodgkin lymphoma (NLP-HL) in the structure 
lymphocytes, histiocytes ora “popcorn” cells are present. Angiogenesis, 
which is necessary for development neoplasma tissue, is stimulated by 
proangiogenic cytokines including Vascular-Endothelial Growth Fac-
tor (VEGF) and basic Fibroblast Growth Factor (bFGF). In HL these cy-
tokines are produced mainly by the R-SC. The aim of the study was 
to assess the concentrations of VEGF and bFGF in the serum (sVEGF, 
sbFGF) in different histopathological types childhood HL. 
Procedure. 37 children with HL were studied: group A – 34 children 
with CHL and group B – 3 children with NCHL. In the control group 
there were 20 children. Using enzyme-linked immunosorbent assays we 
quanti  ed VEGF and bFGF in the serum of the children with HL. 
Results. The median sVEGF in group A was 657.137 pg/ml (43.777–
1210.52) and was signi  cantly higher (p<0.05) in comparison with 
group B  (446.182 pg/ml; 234.673–609.68) and group C (44.6 pg/
ml; 32.2–734.8). In the LDcHL the sVEGF were the highest (865.220, 
1032.665 pg/ml).  
Conclusions. Conclusions. sVEGF in children with cHL are signi  cantly 
higher in relation to the NLP-HL at the moment of diagnosis. There is a 
tendency to different sVEGF in the histopathological types of CHL.
Key words: Cytokines, Angiogenesis, Hodgkin lymphoma, Pediatric
STRESZCZENIE
Wst p. Typy histopatologiczne w klasycznym ch oniaku Hodgkina (cHL) 
ró ni  si  mi dzy innymi procentowym udzia em komórek Reed-Stern-
berga (R-SC) w utkaniu nowotworowym. W typie  z deplecj  limfocy-
tów (LDcHL) w utkaniu nowotworu obecne s  prawie wy cznie R-SC. 
Z kolei w guzkowym typie ch oniaka Hodgkina z przewag  limfocytów 
(NLP-HL) w zaj tej tkance w z owej obecne s  komórki limfocytowe i hi-
stiocytowe lub o typie „popcorn”. Angiogeneza, niezb dna do rozwoju 
tkanki nowotworowej stymulowana jest przez cytokiny proangiogenne: 
Vascular-Endothelial Growth Factor (VEGF) i basic Fibroblast Growth 
Factor (bFGF). Cytokiny te w HL produkowane s  g ównie przez R-SC. 
Celem pracy by a ocena st e  VEGF i bFGF w surowicy (sVEGF, sbFGF) 
w ró nych typach histopatologicznych ch oniaków Hodgkina u dzieci. 
Materia  i metody. Badaniem obj to 37 dzieci z HL. Wyodr bniono 
dwie grupy: grupa A – 34 dzieci z cHL i grupa B – 3 dzieci z NLP-HL. 
Grup  kontroln  (grupa C) stanowi o 20 zdrowych dzieci. Za pomoc  
zestawów Human VEGF i Human FGF basic Quantikine Colorimetric 
Sandwich ELISA  rmy R&D Systems oznaczono sVEGF i sbFGF u bada-
nych dzieci i w grupie kontrolnej.
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Introduction
Hodgkin Lymphomas (HL) account for approximately 
5–7% of all cancer diagnoses in the population of 
children. They are cancers with one of the highest 
rate of complete remissions after the completion of 
treatment. According to the Polish data, the 5-year 
probability of overall survival (OS) is 99%, relapse-
free survival (RFS) 93% and event-free survival 
(EFS) 90% [1, 2]. The HL histopathological classifica-
tion in accordance with WHO is based on a morpho-
logical and immunohistochemical assessment of the 
cells of the affected lymphoid tissue [3–6]. The WHO 
classification distinguishes the Nodular Lymphocyte 
Predominant Hodgkin Lymphoma (NLP-HL), and the 
classical HL (cHL). In the NLP-HL type in the his-
topathological structure are single lymphocytic-his-
tiocytic cells or “popcorn” cells surrounded by nor-
mal lymphocytes. This type is claimed to have the 
best prognosis [7–9]. The histopathological types in 
cHL, cooper others differ percentage of Reed-Stern-
berg cells In affected tissue. The histopathological 
picture of  Lymphocyte Depletion Classical Hodgkin 
Lymphoma (LDcHL) type shows almost only Reed-
Sternberg cells (RSc) and heavy fibrosis with almost 
a complete lack of lymphocytes and reactive cells [4, 
5].
Angiogenesis is crucial for the development of 
tumour tissue. The process of angiogenesis in the body 
is stimulated by cytokines among which the following 
play the key role: Vascular Endothelial Growth Factor 
(VEGF) and basic Fibroblast Growth Factor (bFGF). 
In oncological diseases these cytokines are produced 
mainly by tumour cells, to a lesser extent by the reac-
tive cells accompanying the carcinogenesis, and also 
by the stroma [10, 11]. It has been proved that both in 
adult and children HL these factors are mainly pro-
duced by RS cells which additionally show increased 
expression of receptors for VEGF [10–18]. So, it may 
seem that the greater the number of tumour cells in 
affected lymphoid tissue favors the higher possibility 
of the production proangiogenic cytokines resulting 
in a better vascularisation of the tumour and thus 
in a higher tendency to growth [10, 12, 19]. Accord-
ing to the authors of few studies concerning child-
hood oncology, high serum concentrations of proang-
iogenic markers assessed at diagnosis are autonomic 
and unfavourable prognostic factors in Hodgkin and 
non-Hodgkin Lymphomas in children [15, 20, 21]. Yet 
there have been no reports on the behaviour of proan-
giogenic markers in different histopathological types 
of Hodgkin Lymphomas in children which motivated 
us to analyse this issue. 
Therefore, the aim of the study is the analysis of 
serum concentrations of VEGF and bFGF in children 
with Hodgkin Lymphoma (HL) with respect to the his-
topathological type of the disease as well as its prog-
nostic impact. 
Materials and Methods
The study comprised 37 children (21 boys – 58%; 
15 girls – 42%), aged 4.5–17 (mean 12.8), with Hodg-
kin Lymphoma diagnosed and treated in our institu-
tion between 2000–2008 years. Among the children 
included in the study, the two groups analyzed were 
divided: group A consisting of 34 children (19 boys – 
56%, 15 girls – 44%), aged 4.5–17 (mean 12.7), with 
CHL diagnosed, and group B consisting of 3 children 
(3 boys), aged 12–14 (mean 13.3) with NLP-HL diag-
nosed. In the group A were 3 children (8.8%) with Lym-
phocyte Rich cHL (LRcHL), 22 children (64.7%) with 
Nodular Sclerosis cHL (NScHL), 7 children  (20.6%) 
with Mixed Cellularity cHL (MCcHL) and 2 children 
(5.9%) with LDcHL. The control group (Group C) was 
20 healthy children (13 boys – 65%, 7 girls – 35%; 
aged 2–17; mean 11 years). These children presented 
no abnormalities in physical examination and labo-
ratory tests. 
All children were staged according Ann-Arbor clas-
sification system. The number and location of initial 
disease sites were obtained in each case during a full 
physical examination and chest radiography (x-ray), 
thorax and abdominal computed tomography (CT), 
and cervix,  abdominal and minor pelvis ultrasonog-
Wyniki. Mediana sVEGF w grupie A wynosi a 657,137 pg/ml (43,777–
1210,52) i by a znamiennie wy sza (p<0,05) w porównaniu z grup  B 
(422,177 pg/ml; 234,673–609,68) i grup  C (44,6 pg/ml; 32,2–734,8). 
W typie LDcHL sVEGF by y najwi ksze (865,220, 1032,665 pg/ml). 
Wnioski. W chwili rozpoznania choroby st enia VEGF w surowicy 
u dzieci z klasycznym ch oniakiem Hodgkina s  istotnie wy sze wzgl -
dem typu guzkowego z dominacj  limfocytów. Obserwuje si  tendencj  
do ró nic w surowiczych st eniach VEGF w poszczególnych typach cHL 
u dzieci.
S owa kluczowe: cytokiny, naczyniotworzenie, ch oniak Hodgkina, 
pediatria
357
A c t a  H a e m a t o l o g i c a  P o l o n i c a  t o m  4 3 ,  z e s z y t  n r  4 ,  p a d z i e r n i k - g r u d z i e  2 0 1 2
PRACA ORYGINALNA / ORIGINAL RESEARCH ARTICLE
raphy (USG). All patients had bone marrow biopsies. 
Histopathological subtypes were defined according 
to WHO criteria. The HL were routinely diagnosed by 
two independent pathologists based on histology and 
immunohistochemistry. The material from children 
who were diagnosed with HL before the validity of the 
WHO  classification in Poland was re-evaluated by 
histopathologist. 
From all children (examinated and from control 
group) we were taken 2 cm3  blood for the determination 
of blood concentrations of proangiogenic cytokines in 
the serum. From their parents or guardians and chil-
dren > 16 years of age both HL and from the control 
group were obtained written consent for blood collec-
tion. The consent of the Bioethics Committee of the 
Medical University of Silesia was obtained in order to 
conduct this study. Laboratory tests included serum 
Vascular endothelial growth factor (sVEGF) and basic 
Fibroblast growth factor (sbFGF) concentrations. In 
order to evaluate the VEGF and bFGF concentra-
tion, an additional amount of 2 cm3 was taken dur-
ing routine tests. After coagulation, the blood was 
centrifuged for 20 minutes at 2000 rpm. The serum 
obtained was frozen at -80°C. The analyses were per-
formed using the set Human VEGF Quantikine Color-
imetric Sandwich ELISA, R&D Systems for VEGF and 
FGF basic Quantikine Colorimetric Sandwich ELISA, 
R&D Systems for bFGF. The results of proangiogenic 
markers concentrations were compared with the con-
trol group. 
The analysis additionally included the marking 
at the moment of diagnosis of clinical indicators of 
known prognostic importance such as: age, clinical 
stage of disease, the presence of bulky disease, spleen 
and extra-nodal location of the disease, the presence 
of B symptoms. All patients received uniform treat-
ment according to Protocol Hodgkin Disease 95 based 
on 4–8 cycles of MVPP (mechlorethamine, vinblastin, 
procarbazin, prednisone) and B-DOPA (bleomycin, 
vincristin, adriamycin, dacarbazin, prednisone) with 
or without radiation therapy. These changes in sub-
sequent, control  radiology images gradually disap-
pear. The partial remission (PR) was defined as the 
residual tumor volume was less or equal 50% of the 
initial diameter and  reduction of tumor mass in the 
mediastinum at least 25%. The follow-up ranged from 
34 to 132 months after initial diagnosis (median 74 
months).
Statistics 
Since the distribution of variables was considerably 
different from the normal distribution (Kołmogorow-
Smirnow test), they were described using the median 
(range); the verification of the x hypothesis was per-
formed by means of non-parametric tests. The dif-
ferences between the two groups in relation to indi-
vidual numerical variables were verified using the 
Mann-Whitney U test. Differences and relations with 
p <0.05 were regarded as statistically significant.
Table I. The clinical characteristics of groups A and B
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Results
Clinical characteristics of the examined groups (Ta-
ble I) 
Most children from group A were classified as 
stage II of clinical advancement (n=22; 64%). Extra-
nodal location of the disease was not observed in any 
of the patients. The majority of children (n=28; 82%) 
were in the less favourable age group (> 10 years old). 
24 children (70.6%) from group A did not show the B 
symptoms of the disease. The NScHL type was sig-
nificantly more common in group A (p<0.05). Type 
LDcHL was represented by two patients with adverse 
clinical indicators. 
Complete remission (CR) was observed in 94% 
of the group. Two children (6%) died as a result of a 
generalized infection (Varicella Zoster Virus) in the 
course of drug-induced neutropenia. 
Even though children included in Group B were 
at a less favourable age, they were classified at low 
clinical stages and did not present B symptoms at the 
time of diagnosis. These children achieved complete 
remission of the disease. 
Analysis of serum concentrations of 
proangiogenic cytokines 
The median serum VEGF concentration in group A 
was 657.137 pg/ml (43.777–1210.52) and was sig-
nificantly higher (p<0.05) in comparison with group 
B (446.182 pg/ml; 234.673–609.68) and group C 
(44.6 pg/ml; 32.2–734.8) (Table II). No statistically 
significant differences between the medians of VEGF 
serum concentrations in respective histopathologi-
Table II. The serum VEGF and bFGF concentrations in the groups A, B and C
Tabela II. Surowicze st enia VEGF i bFGF w grupach A,B i C
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cal types of CHL were concluded. In the LDcHL type 
sVEGF were the highest (865.220, 1032.665 pg/ml).
Medians of bFGF concentrations between groups 
A, B and C were not statistically considerable (Table 
II). Amid the histopathological types of CHL in LRCHL 
the lowest serum concentration of bFGF of statistical 
significance was concluded at the moment of diagno-
sis (Table II). 
Discussion
The generally known main prognostic factors in child-
hood HL such as the stage of clinical advancement 
and the presence or lack of B symptoms are beyond 
doubt but new indicators of the activity of the disease 
are still being sought [6, 20]. 
In recent years more attention has been given to 
the role of cytokines in the development of neoplastic 
diseases. The serum concentrations of these proteins 
may reflect both the mass of tumour tissue and the 
level of malignancy of the tumour pattern which in 
turn may have a diagnostic and prognostic signifi-
cance. The unfavourable prognostic significance of 
high serum concentrations of Interleukin-10, Tumor 
Necrosis Factor-alfa and Transforming Growth Fac-
tor-beta assessed in the process of diagnosing neo-
plastic diseases, including HL has been proven [4, 6]. 
Recent reports suggest proangiogenic cytokines 
(VEGF and bFGF) play a role in the development 
of HL. These factors, according to the majority of 
authors are produced by RSc and to a lesser extent by 
reactive cells accompanying the carcinogenesis [11, 
12, 14–18, 22–25]. Observations made by the authors 
unanimously conclude that in patients with oncologi-
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cal diseases, both adults and children, there are high 
concentrations of the above-mentioned cytokines at 
diagnosis and their significant reduction after remis-
sion has been achieved. Exceptionally high values at 
the moment of diagnosis and their slight reduction 
after the therapy are related with a higher tendency 
for the recurrence of the disease or its progression 
[11, 14, 22, 23, 26, 27]. There are single works prov-
ing that high serum concentrations of proangiogenic 
markers assessed at diagnosis are unfavourable 
prognostic factors in childhood Hodgkin Lymphomas 
[14, 20, 21, 23]. 
Recently greater attention has been given to the 
impact of respective histopathological types on the 
prognosis.  Nodular Lymphocyte Predominant Hodg-
kin Lymphoma in whose pattern single lymphocytic-
histiocytic cells or “popcorn” cells surrounded by nor-
mal lymphocytes are observed, was distinguished [4, 
5]. Low histopathological malignancy of the NLP-HL 
according to clinical observations usually results in a 
low level of clinical advancement and often in a lack 
of B symptoms. The above-mentioned is reflected in 
the good results of the therapy as noted by Pellegrino 
at al. [7], Murphy at al. [8] and Sandowal et al. [9]. 
The authors emphasize the validity of minimizing 
the treatment in children with NLP-HL, which has 
already been observed in new therapeutic protocols 
for children [28].
Low production of proangiogenic cytokines, espe-
cially of VEGF by the tumour tissue poor in tumour 
cells may be also a factor contributing to a good prog-
nosis. According to our observations, children with 
NLP-HL had a statistically lower initial concentration 
of VEGF in the serum. They were classified to low 
clinical stages of disease, did not present B symptoms 
and achieved complete remission. The serum concen-
tration of VEGF may constitute both a diagnostic 
and prognostic marker in new therapeutic protocols. 
However more research is needed with respect to the 
above-mentioned issue.  
In classical HL four histopathological types have 
been distinguished. According to the WHO classifi-
cation the division is based above the others on the 
assessment of reactive cells such as lymphocytes, 
eosinophiles, histiocytes, fibroblasts and neutrophils 
and the stage of the accompanying fibrosis. In the 
LRcHL type the histopathological picture is domi-
nated by lymphocytes and reactive cells, with mini-
mal participation of R-SC and accompanying fibrosis. 
In turn, in the LDcHL type, are almost only R-SC and 
significant fibrosis with nearly complete lack of lym-
phocytes and reactive cells [4, 5]. 
In our material we have observed the highest 
sVEGF in LDcHL which confirms that the cytokines 
are produced by the tumour cells. Despite the dif-
ferentiation of clinical stages of disease (II and III), 
the sVEGF in respective children were high. However 
more research is needed with respect to the above-
mentioned issue.  Following chemotherapy children 
with LDcHL achieved the state of partial remission 
(25% reduction of mediastinal mass). After a 4-year 
observation they have a stable tendency to reduce the 
residual lesions. The children require constant obser-
vation which is stressed by Ben Arush et al. [14], who 
describe the correlation between high initial serum 
concentrations of VEGF and the relapse of the dis-
ease in children with HL.  
Both the diagnostic and prognostic values of bFGF 
in HL seem to be of less significance. In the presented 
material the invariably lower median of bFGF concen-
trations in the NLP-HL group in relation to the cHL 
group and only significantly the lowest median in the 
LRcHL type may confirm the multidirectional action 
of this cytokine. According to Khnytkin et al. [29] who 
examined the expression of the bFGF cytokine and 
its receptors, only the FGFR3 expression is observed 
in R-SC. According to the authors oxygen deficiency 
stimulating angiogenesis in the tumour cell induces 
the expression of VEGF and not bFGF. The bFGF 
receptors seem to express only in R-SC of selected 
phenotypes [28]. 
Since the presented study is based on a small and 
piloting group of children, the issues raised warrant 
further study. However, we would like to stress the 
tendency to a correlation between the concentrations 
of proangiogenic cytokines in the serum and his-
topathological types of Hodgkin Lymphomas in chil-
dren. The above report confirms the conclusion made 
by the authors that the research concerning angio-
genesis in childhood HL is valid and may be in the 
future used in antiangiogenic treatment in resistant 
types of HL [14, 15, 18, 19].
Conclusions
VEGF concentrations in the serum in children with 
classical Hodgkin Lymphoma are significantly high-
er in relation to the Nodular Lymphocyte Predomi-
nant Hodgkin Lymphoma at the moment of diagno-
sis which may be an additional prognostic factor in 
childhood HL. 
There is a tendency to differences in serum VEGF 
concentrations in respective types of classical HL in 
children.
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